PhEAST
Pharyngeal Electrical Stimulation for Acute Stroke dysphagia Trial
UK ISRCTN 98886991
UK IRAS306761
UK CPMS50913
WHO UTN U1111-1273-9942
Home Synopsis Co-enrolment Contact us

Welcome

This site has been created as a resource for PhEAST researchers, co-ordinating centres, participants, relatives and carers alike.  We hope you enjoy browsing our site and finding all the information you need!

Synopsis

Title Pharyngeal Electrical Stimulation for Acute Stroke dysphagia Trial
Acronym PhEAST
Short title Pharyngeal Electrical Stimulation for Post Stroke dysphagia
Chief investigator Professor Philip M Bath
Objectives

Overall
To assess whether Pharyngeal Electrical Stimulation (PES) is safe and effective at improving post-stroke dysphagia (PSD).

Primary
  • Does 6 days of PES accelerate return to oral intake of food and drink as assessed using the dysphagia severity rating scale and blinded to treatment?
Secondary
  • Does PES improve swallowing and reduce pneumonia, antibiotic exposure, hospital length of stay and disability?
  • Does PES increase quality-of-life?
  • Is PES cost effective as compared to usual care?
  • What subgroups predict response to PES?
Trial configuration International prospective randomised open-label blinded-endpoint (PROBE) parallel group superiority phase IV effectiveness trial
Setting Secondary care: acute stroke services
Sample size estimate

The null hypothesis is that PES does not alter DSRS at day 14 post recruitment in participants with PSD. The primary outcome, DSRS (dysphagia severity rating scale) will be compared between PES and no PES using multiple linear regression with adjustment for stratification and minimisation variables.

Assuming alpha 5%, power 90%; DSRS difference 1.2, standard deviation 5.0; losses 3%, crossovers 3%; sample rounded up, a sample size of N=800 is needed (PES n=400, control n=400) (assumptions based on pilot trials and STEPS trial).

Number of participants 800
Eligibility criteria Inclusion:

800 hospitalised adults (age ≥18) with recent (4-31 days) ischaemic or haemorrhagic anterior or posterior circulation stroke (as diagnosed clinico-radiologically) at a stroke centre, and clinical dysphagia defined as a functional oral intake scale (FOIS) score of 1 (nothing by mouth, feeding by naso-gastric tube [NGT]/percutaneous endoscopic gastrostomy [PEG] tube) or 2 (tube dependent with minimal attempts of food or liquids).  NIHSS item 1a score of 0, 1 or 2 (where the patient requires repeated stimulation to arouse).


Excluded:

Non-stroke dysphagia, e.g., due to traumatic brain haemorrhage, subarachnoid haemorrhage, brain tumour, Parkinson's disease, multiple sclerosis, severe dementia, head or neck cancer.  NIHSS item 1a score of 2 (where the patient only responds to pain) or NIHSS item 1a score of 3.  Pre-stroke dysphagia or dependency (modified Rankin scale, mRS 4/5).  Patient expected to be repatriated to a separate organisation.  Patient expected to be rehabilitated at a separate organisation.  Patient not likely to be in the treating hospital for at least 14 days.  Ongoing or anticipated ventilation/intubation/tracheostomy or use of electrical or magnetic stimulation.  Malignant middle cerebral artery syndrome.  Pregnant.  Pacemaker.  Need for >35 litres of oxygen.  Two or more NGT pulled out unless nasal bridle in place.  Investigator feels patient will not tolerate PES catheter.

Description of interventions Intervention arm

PES on top of guideline-based standard-of-care. PES will be administered on days 1-6 using a commercial catheter with integral feeding tube. PES involves six daily 10 minute treatments at 5 Hz; threshold and tolerability currents will be assessed and the treatment current set at threshold + 0.75 x (tolerability - threshold) with current generated by a base-station. Dosing levels will be monitored, and sites informed if the stimulation current is too low, i.e. <20 mA; sites will be re-trained on the importance of delivering adequate current, if necessary. The catheter will be replaced once only if pulled out before 3 treatments have been administered. Treatment will be administered by PES-trained research coordinators, nurses or SLTs who are not involved in outcome data collection.

Comparator arm

No PES catheter/stimulation on top of best guideline-based standard-of-care dysphagia management. A standard NGT will be used for feeding as necessary.

Duration of study From randomisation: treatment for 6 days, primary outcome at day 14, final follow-up at day 90. Trial and funding 3.25 years. Secondary endpoint at Day 365 (all cause mortality).
Randomisation and blinding Randomised 1:1 with stratification on country and minimisation on age, sex, dysphagia severity rating scale (DSRS), impairment (National Institutes of Health stroke scale [NIHSS]), stroke type (ischaemic/haemorrhagic), circulation (anterior/posterior), time to randomisation; with 10% simple randomisation. Treatment will be delivered by a dedicated member of staff not otherwise involved in the trial. Outcomes will be assessed by other staff blinded to randomised treatment.
Outcome measures

Primary at day 14±1
Dysphagia assessed using DSRS, based on bedside clinical assessment/management conducted at days 14±1. Outcome assessment will be assessed by DSRS/FOIS-trained research coordinators, nurses or SLTs who are not involved in treatment.

Secondary at day 7±1
PES threshold, tolerability and stimulation currents; number of catheters used.

Secondary at day 14±1
DSRS >3, FOIS, EAT-10 and feeding status score (FSS); NGT/PEG in situ; pneumonia; antibiotic use; weight; EQ5D-5L, EQ-VAS (source recorded - patient or proxy).

Note 1: We have included several measures of dysphagia and feeding: DSRS, FOIS, EAT-10 and FSS to triangulate the presence and magnitude of dysphagia and effects on feeding. These will be analysed together using the Wei-Lachin test.

Secondary at discharge/death by hospital assessor blinded to treatment:
Length of stay; antibiotic use; swallowing therapy contact time; time to removal of NGT/PEG; admitted to ICU; discharged with PEG; disposition (home, residential home, nursing home, hospital, death).

Secondary at day 90±7 by central telephone assessor blinded to baseline, treatment and in-hospital data (or by post)
DSRS, FOIS, EAT-10, FSS; home time; dependency (modified Rankin Scale), disability (Barthel Index), quality of life (EQ-5D5L/EQ-VAS.), cognition (TICS), mood (Zung); disposition.
Note 1: These outcomes are all sensitive to therapeutic change.

Secondary at day 365
All cause mortality.

Safety
PES has an excellent safety record in previous trials. Participants with PSD, who usually have severe stroke, will have multiple adverse events and SAEs. Hence, we will limit recording to: SAEs over 0-7 days, procedure/device-related (S)AEs over days 0-14; fatal SAEs over days 8-90 days; and all-cause mortality to day 365.

Costs
Health care resource use at discharge and day 90.

Statistical methods

The primary outcome, DSRS, will be compared between PES and no PES using multiple linear regression with adjustment for stratification and minimisation variables. The null hypothesis is that PES does not alter DSRS at day 14 in participants with PSD.

Assuming alpha 5%, power 90%; DSRS difference 1.2, standard deviation 5.0; losses 3%, crossovers 3%; sample rounded up, a sample size of N=800 is needed (PES n=400, control n=400).

Co-enrolment

PhEAST has co-enrolment agreements in place with the following trials
 
Trial Delay to PhEAST
(patients cannot be enrolled into PhEAST after number of days shown, after enrolment into the other study)
ENOS-2≥ 4 days
MAPS-2≥ 4 days
ReCAST-3≥ 14 days
TICH-3≥ 14 days
ProFATE (NUH)≥ 14 days
MACE-ICH (NUH)≥ 14 days

Others will be added as approved.

Contact us

Room S/D2108
Stroke Trials Unit
School of Medicine
University of Nottingham
Queen's Medical Centre
Derby Road
Nottingham NG7 2UH
United Kingdom

For any queries, please email us.

Other documents